Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC
Status:
Recruiting
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
The purpose of the initial (phase I) portion of this study is to find a dose level and
administration schedule of the study drug, 225Ac-J591 that can be given without severe side
effects.